News
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...
Drugmaker Novo Nordisk announced Tuesday that Wegovy will be available through telehealth providers. The providers -- Hims & ...
Hims & Hers Health (NYSE: HIMS) stock surged 23% on Tuesday, April 29, after Novo Nordisk announced plans to offer popular ...
Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ...
In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.
Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans. Hims & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback